Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.55
  • Today's Change-0.10 / -6.06%
  • Shares traded8.52m
  • 1 Year change-78.32%
  • Beta1.4942
Data delayed at least 20 minutes, as of May 03 2024 17:07 BST.
More ▼

Profile data is unavailable for this security.

About the company

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.

  • Revenue in GBP (TTM)7.21m
  • Net income in GBP-46.89m
  • Incorporated2015
  • Employees28.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Genflow Biosciences PLC0.00-1.18m7.17m0.007.17m0.00
ImmuPharma PLC69.96k-2.99m7.91m13.007.91m13.00
Cambridge Nutritional Sciences PLC9.05m-3.21m9.40m91.009.40m91.00
Bivictrix Therapeutics PLC0.00-2.33m9.49m10.009.49m10.00
Proteome Sciences plc5.03m-2.44m10.36m35.0010.36m35.00
Chill Brands Group PLC146.62k-3.64m11.64m2.0011.64m2.00
Kanabo Group PLC895.00k-7.99m11.70m20.0011.70m20.00
Abingdon Health PLC5.34m-2.24m11.87m82.0011.87m82.00
Shield Therapeutics PLC7.21m-46.89m12.12m28.0012.12m28.00
Synairgen plc0.00-9.99m12.49m30.0012.49m30.00
Incanthera PLC0.00-1.48m12.91m8.0012.91m8.00
Genincode PLC1.72m-6.73m13.05m28.0013.05m28.00
Provexis plc598.08k-496.59k14.71m2.0014.71m2.00
Oncimmune Holdings PLC1.15m-6.15m17.05m56.0017.05m56.00
LungLife AI Inc36.67k-4.32m17.15m15.0017.15m15.00
Destiny Pharma PLC0.00-5.66m17.39m20.0017.39m20.00
Data as of May 03 2024. Currency figures normalised to Shield Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

32.36%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Advisors (UK) Ltd.as of 18 May 202344.97m5.75%
Jupiter Asset Management Ltd.as of 21 Jul 202334.13m4.36%
Hargreaves Lansdown Asset Management Ltd.as of 05 May 202333.97m4.34%
IG Markets Ltd.as of 08 Feb 202430.05m3.84%
Premier Fund Managers Ltd.as of 05 May 202330.00m3.84%
LGT Capital Partners AG (Investment Management)as of 08 Feb 202428.70m3.67%
KW Investment Management Ltd.as of 08 Feb 202418.60m2.38%
Maitland Asset Management (Pty) Ltd.as of 08 Feb 202411.09m1.42%
Jarvis Investment Management Ltd.as of 08 Feb 202410.92m1.40%
Killik & Co. LLPas of 05 May 202310.62m1.36%
More ▼
Data from 30 Jun 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.